Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
The company reported an EPS loss of $(2.06) or (1.91 euros), missing the consensus loss of $(1.56) and down from a loss of 2.16 euros a year ago.Tuesday, Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.
星期二，Ascendis Pharma A/S (納斯達克: ASND) 報告了第二季度銷售額達到$38.76 million (35.90 million euros)，低於市場預期的$92.70 million，較一年前的47.40 million euros有所下降。
Results in the quarter were primarily impacted by a negative adjustment to prior periods' estimates and assumptions for sales deductions of 27.1 million euros, where 19.5 million euros and 7.6 million euros were attributable to the three months ended March 31, 2024, and periods before January 1, 2024, respectively.
本季度的結果主要受到先前期間銷售扣除預估和假設的負面影響，金額爲27.10 million euros，其中19.50 million euros和7.60 million euros分別歸屬於2024年3月31日結束的三個月和2024年1月1日之前的期間。
Also Read: Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues.
此外，閱讀：Ascendis 的甲狀旁腺功能減退症藥物獲得 FDA 批准，成爲首個和唯一的治療方案，取代了因供應問題而停產的武田藥物。
The company reported an EPS loss of $(2.06) or (1.91 euros), missing the consensus loss of $(1.56) and down from a loss of 2.16 euros a year ago.
該公司報告的每股收益虧損爲$（2.06）或（1.91 euros），低於市場預期的虧損$（1.56）和一年前的虧損2.16 euros。
Skytrofa, indicated as a once-weekly pediatric growth hormone treatment, generated revenue of 26 million euros, a 27% decrease year over year. The 134% year over year volume growth was offset by the cost associated with broader market access.
作爲一種每週一次的小兒生長激素治療，Skytrofa 的收入爲2600萬 euros，同比下降27%。134%的年度成交量增長被與更廣泛市場接入相關的成本抵消。
Recently approved hypoparathyroidism drug Yorvipath's revenue totaled €5.2 million, reflecting the first full quarter of commercial launch in Germany and Austria as well as initial revenue in International Markets. Initial revenue in France is expected to start in the fourth quarter of 2024.
最近獲得批准的甲狀旁腺功能減退症藥物 Yorvipath 的收入總額達到€520萬，反映了在德國和奧地利的商業推出的第一個完整季度以及國際市場的初步收入。法國的初步收入預計將於2024年第四季度開始。
Guidance: Ascendis Pharma has lowered its fiscal year 2024 sales guidance for Skytrofa to 220 million euros – 240 million euros from prior guidance of 320 million euros to 340 million euros.
指導：Ascendis Pharma 已將其2024財年 Skytrofa 銷售指導下調至2.20億 euros - 2.40億 euros，較先前指導的3.20億 euros - 3.40億 euros有所降低。
Concurrently, the company entered into a capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath with Royalty Pharma plc (NASDAQ:RPRX).
同時，公司與 Royalty Pharma plc (納斯達克: RPRX) 就 Yorvipath 在美國市場的淨銷售額達成了限額合成皇家利息融資協議。
Under the terms of the agreement, Ascendis receives an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of Yorvipath. The royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.0x or 1.65x if Royalty Pharma receives royalties in that amount by December 31, 2029.
根據協議條款，Ascendis Pharma A/S收到1500萬美元的預付款，以交換3%的美國Yorvipath淨銷售額的專利收費。Royalty Pharma將在截至2029年12月31日之前達到2.0倍或1.65倍的倍數時停止向其支付專利費。
Price Action: ASND stock is down 15% at $114.50 during the premarket session at last check Wednesday.
價格走勢:週三最後一次查詢預市盤中ASND股票下跌15%，報114.50美元。
Photo via Shutterstock
圖片來自shutterstock。
Read Next
閱讀下一篇
- Dollar Tree Q2 Earnings: Revenue And EPS Miss, Cuts Annual Forecasts As Customers Feel Macro Pressure On Spending, Stock Tumbles.
- 美元樹公司第二季度業績:營業收入和每股收益不及預期，由於消費者感受到宏觀經濟壓力，公司削減了年度預測，股價下跌。
譯文內容由第三人軟體翻譯。
